are all relevant. These data provide confidence and expand our understanding for dosing in follitropin delta."

Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of dosing strategies, making it the only recombinant FSH with robust clinical evidence supporting multiple dosing strategies. Ferring will take forward the implications of this study in future dialogue with regulatory authorities."

About GnRH protocols

Gonadotrophin-releasing hormone (GnRH) agonists and antagonists are used as concomitant treatment during ovarian stimulation to prevent premature luteinisation and ovulation for IVF/ICSI.7,8

About Follitropin Delta (Rekovelle®)

Follitropin delta is a human cell line-derived rFSH with an approved dosing algorithm designed for a predictable ovarian response.3It is the firs
=*=*=*=*=*=
当前为第4/8页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页